scholarly journals Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis

2021 ◽  
Author(s):  
Jana Hashash
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Combination Therapy ◽  
Maintenance Of Remission ◽  
Biologic Monotherapy

279 COMBINATION THERAPY DOES NOT IMPROVE CLINICAL AND ENDOSCOPIC REMISSION RATES WITH VEDOLIZUMAB OR USTEKINUMAB IN CROHN'S DISEASE AND ULCERATIVE COLITIS

2020 ◽  
Vol 158 (6) ◽  
pp. S-53
Author(s):  
Anne Hu ◽  
Paulo G. Kotze ◽  
William Tan ◽  
Alison T. Jess ◽  
Pei-Shun Mimi Li ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Combination Therapy ◽  
Endoscopic Remission ◽  
Remission Rates

scholarly journals Antibiotics and probiotics in inflammatory bowel disease: when to use them?

2019 ◽  
Vol 11 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Bincy Abraham ◽  
Eamonn M M Quigley
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Initial Therapy ◽  
Infectious Complications ◽  
Inflammatory Bowel ◽  
Maintenance Of Remission ◽  
Randomised Controlled

Antibiotics and probiotics are often used as adjunctive therapy in inflammatory bowel disease. However, data are limited and randomised controlled trials are too inconsistent to provide generalised recommendations for their use in all patients with ulcerative colitis or Crohn’s disease. Antibiotics are best used in the management of infectious complications and fistulas in Crohn’s disease and, perhaps, in reducing the intensity of inflammation in luminal disease. Ciprofloxacin, metronidazole and rifaximin have been most widely used and studied. On the other hand, there appears to be a limited role for antibiotics in ulcerative colitis (UC). Probiotics are most effective in pouchitis, and may have a role in the initial therapy and maintenance of remission in mild UC; the probiotic cocktail VSL#3 has been the most widely studied. There is scant evidence of efficacy for probiotics in Crohn’s disease.

Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn’s disease with upper gastrointestinal involvement in a biologic-experienced individual

2021 ◽  
Vol 14 (10) ◽  
pp. e243500
Author(s):  
Na Yu ◽  
Dhruv Sarwal ◽  
Ryan Ash ◽  
Florence M Aslinia
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Combination Therapy ◽  
Triple Therapy ◽  
Inflammatory Process ◽  
Gastrointestinal Involvement ◽  
Upper Gastrointestinal ◽  
Experienced Individual ◽  
Biologic Monotherapy

Induction of remission in biologic-experienced individuals with moderate to severe Crohn’s disease (CD) can be a challenge. We hereby present a case of CD with secondary non-response to infliximab. Adding methotrexate and switching to ustekinumab plus methotrexate did not stop the inflammatory process. Therefore, combination therapy with two classes of biologics consisting of ustekinumab and adalimumab plus methotrexate was initiated. He achieved clinical remission in 4 weeks and remained on triple therapy for 6 months which was subsequently tailored to adalimumab/methotrexate combination therapy due to insurance restriction on ustekinumab. He remained in remission for the duration of follow-up, 14 months after initiation of triple therapy and 8 months after switching to methotrexate/adalimumab biologic monotherapy. Triple therapy with anti-TNF, IL-12/23 inhibitor and methotrexate could potentially be an option for induction of remission in biologic-experienced individuals with good initial clinical response to anti-TNF agents.

Mannan-binding lectin gene polymorphisms in ulcerative colitis and Crohn's disease

2001 ◽  
Vol 120 (5) ◽  
pp. A459-A459
Author(s):  
A RECTOR ◽  
P LEMEY ◽  
W LAFFUT ◽  
E KEYAERTS ◽  
F STRUYF ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Gene Polymorphisms ◽  
Lectin Gene ◽  
Mannan Binding Lectin ◽  
Binding Lectin

Is reduction from adalimumab 80mg to 40mg sufficient for maintenance of remission in patients with Crohn's disease?

2007 ◽  
Vol 45 (08) ◽  
Author(s):  
M Jürgens ◽  
J Seiderer ◽  
S Brand ◽  
S Pfennig ◽  
B Göke ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Maintenance Of Remission

RDW can be a useful additional marker in diagnosing Crohn's disease and ulcerative colitis

2008 ◽  
Vol 46 (05) ◽  
Author(s):  
Z Szepes ◽  
K Farkas ◽  
T Molnar ◽  
F Nagy ◽  
T Nyari ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Additional Marker
Sign in / Sign up

Export Citation Format

Share Document